ICLs effective over long-periods

Article

The use of implantable collamer lenses (ICLs) to correct moderate to high myopia can offer predictable and stable results over a long period of time, according to a report published in the July issue of Archives of Ophthalmology.

The use of implantable collamer lenses (ICLs) to correct moderate to high myopia can offer predictable and stable results over a long period of time, according to a report published in the July issue of Archives of Ophthalmology.

Kazutaka Kamiya, MD, PhD and colleagues from the University of Kitasato School of Medicine and Sanno Hospital, Tokyo, Japan conducted a study to determine the long-term clinical outcomes of implantation of a biocompatible collagen copolymer lens (Visian ICL, STAAR Surgical) in patients with high to moderate myopia. A total of 56 eyes (34 patients) with myopic refractive errors of -4 to -15.25 D received the lens and follow-up examinations were conducted 1, 3 and 6 months and 1, 2 and 4 years following surgery.

At four years postoperative, 79% of eyes were within ±0.5 D of target refraction and 93% were within ±1 D of target refraction. Mean manifest changes in refraction of -0.24 D occurred from 1 month to 4 years and no vision-threatening complications were observed.

The results of this study suggest that ICLs are safe and effective and can offer stable refractive results even over long time periods making them a suitable treatment option for eyes with moderate to high myopia.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.